Diabetic Cardiomyopathy

Total Page:16

File Type:pdf, Size:1020Kb

Diabetic Cardiomyopathy EDITORIAL (SEE BERTONI ET AL., P. 2791) Diabetic Cardiomyopathy t has been over 30 years since Rubler et 60% in well-controlled type 2 diabetic pa- and induce myocardial inflammation al. (1) described four diabetic patients tients. Therefore, it is not surprising that through stimulation of poly(ADP-ribose) I with congestive heart failure (CHF), in this issue of Diabetes Care, Bertoni et al. polymerase-1; yet poly(ADP-ribose) normal coronary arteries, and no other (9) have documented that the diagnosis of polymerase-1 inhibition prevents and re- etiologies for CHF and proposed that it idiopathic cardiomyopathy is more com- verses these effects (19). Lipotoxicity due was due to diabetic cardiomyopathy. mon in the diabetic patient. to the elevation of free fatty acids (FFAs) Eight years ago, I reviewed the evidence While these studies of diastolic dys- associated with hyperglycemia and/or in- for diabetic cardiomyopathy as a unique function were performed in diabetic pa- sulin resistance may also be a factor be- entity unassociated with coronary artery tients with a normal left ventricular mass, cause FFAs and their oxidation products disease and concluded that diabetic car- left ventricular hypertrophy is more prev- may be directly toxic to the myocardium diomyopathy was a distinct entity charac- alent in type 2 diabetic patients and con- and contribute to the development of di- terized by diastolic dysfunction, which tributes to ventricular dysfunction. In the abetic cardiomyopathy (20). was rarely clinically apparent unless asso- Framingham Heart study, diabetic Since diabetic cardiomyopathy is ciated with hypertension (when it was women had a left ventricular mass 10% now known to have a high prevalence in likely to become clinically apparent) greater than that of their nondiabetic the asymptomatic type 2 diabetic patient, and/or with myocardial ischemia (when it peers; and in the Tayside Study, left ven- screening for its presence at the earliest was likely to present with severe clinical tricular hypertrophy was present in 32% stage of development would be appropri- manifestations) (2). At that time the evi- of normotensive type 2 diabetic subjects ate in order to prevent the progression to dence also suggested that diastolic dys- who were not utilizing ACE inhibitors and CHF. The most sensitive test for that is a function was due to myocellular had no known coronary artery disease (10, standard echocardiogram with pulsed- hypertrophy and myocardial fibrosis, and 11). Unlike myocardial fibrosis, which is wave Doppler examinations during the at the cellular level there were defects in likely due to hyperglycemia, left ventric- second stage of the Valsalva maneuver calcium transportation, myocardial con- ular hypertrophy is most likely related to (7,8). However, the cost of this screening tractile protein collagen formation, and the insulin resistance syndrome (12). is prohibitive, and a less expensive pre- fatty acid metabolism (2). Since then we The high prevalence of diastolic dys- screening method needs to be devised. have learned that diabetic cardiomyopa- function is due to myocardial fibrosis, and Fortunately, detection of microalbumin- thy is not a rare condition but instead a in the Strong Heart Study, the extent and uria, which should be performed annu- very common one, and that its etiology is frequency of diastolic dysfunction was di- ally in all diabetic patients, is an adequate largely due to hyperglycemia with con- rectly proportional to the HbA1c level prescreening test. The Strong Heart Study tributions from the insulin resistance (13,14). The most likely reason for this (21) showed that the degree of diastolic syndrome that cause left ventricular intimate association is the accumulation dysfunction was proportional to the level hypertrophy. of advanced glycosylation end products of microalbuminuria, even after adjusting Left ventricular diastolic dysfunction (AGEs) in the myocardium (15). In ani- for age, sex, BMI, systolic blood pressure, is characterized by impairment in early mal studies the presence of diabetes re- duration of diabetes, left ventricular mass, diastolic filling, prolongation of isovolu- sults in increased myocardial AGE and presence of coronary artery disease. metric relaxation, and increased atrial fill- receptor expression, increased cross- Furthermore, the Heart Outcomes Pre- ing, and these characteristics have even linking of collagen, and myocardial fibro- vention Evaluation (HOPE) (22) study been documented in young type 1 dia- sis. With lysis of the collagen cross-links, showed that the presence of microalbu- betic patients (3). Older studies (4–6) of there was a decrease in myocardial fibro- minuria was associated with significant well-controlled type 2 diabetic subjects sis and an improvement in diastolic dys- risk for CHF. Because microalbuminuria showed that 30% had diastolic dysfunc- function (16). Intracellular myocardial is a marker of endothelial dysfunction in tion. However, this prevalence was based glycation also alters calcium homeostasis, the glomerulus, which is an arteriole, it is on standard echocardiography testing, in leading to myocardial dysfunction, which logical to postulate that endothelial dys- which mild and early diastolic dysfunc- can be reversed with an aminoguanidine- function in the myocardium leads to in- tion is not detectable in approximately induced reduction in glycosylation (17). creased ventricular scarring and stiffness one-third of subjects. When more rigor- In animal studies, activation of protein ki- (2). Therefore, the presence or develop- ous Doppler methods are used, early and nase C (PKC)-␤ activity by hyperglycemia ment of microalbuminuria warrants the mild diastolic dysfunction can be diag- has resulted in myocardial necrosis and cost of echocardiography with pulsed- nosed. Using these methods in Olmstead fibrosis and ventricular dysfunction, wave Doppler evaluation, even in the County, Minnesota, 52% of diabetic sub- which again improved with the inhibition asymptomatic diabetic patient. jects were shown to have diastolic dys- of PKC-␤ (18). Hyperglycemia also in- Documentation of diastolic dysfunc- function (7). Using similarly sensitive creases the myocardial content of free rad- tion should result in the initiation of ther- methods, Porier et al. (8) showed the icals and oxidants, which decrease nitric apy to prevent advancement to heart prevalence of diastolic dysfunction to be oxide levels, worsen endothelial function, failure. Achievement of glycemic control, DIABETES CARE, VOLUME 26, NUMBER 10, OCTOBER 2003 2949 Editorial preferably with agents that reduce insulin 20th St., Birmingham, AL 35294-3407. E-mail: good DT, Gorlin R, Shimabukuro S: Rela- resistance, is essential. In the future, the [email protected]. tion among left ventricular mass, insulin D.S.H.B. has served as a consultant for and re- resistance, and blood pressure in nono- availability of agents that prevent or re- ceived honoraria from Abbott Laboratories and verse glycosylation and cross-linking of bese subjects. J Clin Endocrinol Metab 83: GlaxoSmithKline Pharmaceuticals. 4284–4288, 1998 collagen or decrease lipotoxicity or its ef- © 2003 by the American Diabetes Association. 13. Shehadeh A, Regan TJ: Cardiac conse- fects will be helpful. At the present time, ␤ quences of diabetes mellitus. Clin Cardiol we know that -blockers and thiazo- ●●●●●●●●●●●●●●●●●●●●●●● 18:301–305, 1995 lidinediones shift the metabolism of the References 14. Devereux RB, Roman MJ, Paranicas M, myocardium from the use of FFAs to that 1. Rubler S, Dlugash J, Yuceoglu YZ, Kumral O’Grady MJ, Lee ET, Welty TK, Fabsitz of glucose (23,24). In addition, thiazo- T, Branwood AW, Grishman A: New type RR, Robbins D, Rhoades ER, Howard BV: lidinediones have been shown in animals of cardiomyopathy associated with dia- Impact of diabetes on cardiac structure to decrease myocardial FFA content and betic glomerulosclerosis. Am J Cardiol 30: and function: the Strong Heart Study. Cir- their toxic metabolites and improve ven- 595–602, 1972 culation 101:2271–2276, 2000 tricular function (25). The initial defini- 2. Bell DSH: Diabetic cardiomyopathy: a 15. Bauters C, Lamblin N, McFadden EP, Van tive therapy should be the use of ACE unique entity or a complication of coro- Bell E, Millaire A, DeGroote P: Influence naryarterydisease?DiabetesCare18:708– of diabetes mellitus on heart failure risk inhibitors, which decrease left ventricular 714, 1995 and outcome. Cardiovasc Diabetol 2:1–16, hypertrophy and myocardial fibrosis, 3. Schannwell CM, Schneppenheim M, Per- 2003 prevent myocardial remodeling, improve ings S, Plehn G, Strauer BE: Left ventric- 16. Candido R, Forbes JM, Thomas MC, Thal- endothelial function, and lower insulin ular diastolic dysfunction as an early las V, Dean RG, Burns WC, Tikellis C, resistance (26). Because the new diagnos- manifestation of diabetic cardiomyopa- Ritchie RH, Twigg SM, Cooper ME, Bur- tic criteria for heart failure regard the thy. Cardiology 98:33–39, 2002 rell LM: A breaker of advanced glyca- presence of diabetes as stage 1 heart fail- 4. Di Bonito P, Cuomo S, Moio N, Sibilio G, tion end products attenuates diabetes- ure, even the addition of a ␤-blocker at Sabatini D, Quattrin S, Capaldo B: Dia- induced myocardial structural changes. this early stage to prevent or reverse any stolic dysfunction in patients with non- Circ Res 92:785–792, 2003 present myocardial remodeling is appro- insulin-dependent diabetes mellitus of 17. Ziegelhoffer A, Ravingerova T, Styk J, Se- short
Recommended publications
  • Diabetes Reduces Left Ventricular Ejection Fraction-Irrespective Of
    European Journal of Endocrinology (2011) 165 945–951 ISSN 0804-4643 CLINICAL STUDY Diabetes reduces left ventricular ejection fraction-irrespective of presence and extent of coronary artery disease Niklas F Ehl1, Michael Ku¨hne1, Miriam Brinkert1, Jan Mu¨ller-Brand2 and Michael J Zellweger1 Departments of 1Cardiology and 2Nuclear Medicine, University Hospital, Petersgraben 4, CH - 4031 Basel, Switzerland (Correspondence should be addressed to M J Zellweger; Email: [email protected]) Abstract Background: It is not clear whether diabetes reduces systolic left ventricular function (left ventricular ejection fraction, LVEF) irrespective of coronary artery disease (CAD). The aim of this study was to compare the LVEF between diabetic and non-diabetic patients with respect to the extent of CAD. Methods and results: Consecutive patients undergoing stress myocardial perfusion SPECT (MPS) were evaluated. MPS was interpreted using a 20-segment model with a five-point scale to define summed stress score (SSS), summed rest score, and summed difference score. LVEF was measured by gated SPECT and then compared with respect to diabetic status and SSS categories. Of 2635 patients, data of 2400 was available. Of these, 24% were diabetic, mean age was 64G11y, and 31% were female. Diabetics had a significantly lower LVEF compared with non-diabetics regardless of the extent of CAD: 53G13 and 55G13% respectively (PZ0.001). Diabetics and non-diabetics did not differ significantly in the distribution of SSS categories. Diabetes was an independent predictor of decreased LVEF (odds ratio 1.6, 95% confidence interval 1.2–2.0; P!0.001). Conclusion: Diabetics had a lower LVEF than non-diabetics.
    [Show full text]
  • Treatment Options in Myocarditis and Inflammatory Cardiomyopathy
    Main topic Herz 2018 · 43:423–430 B. Maisch1 ·P.Alter2 https://doi.org/10.1007/s00059-018-4719-x 1 Fachbereich Medizin, Philipps-Universität Marburg und Herz- und Gefäßzentrum (HGZ) Marburg, Published online: 15 June 2018 Marburg, Germany © The Author(s) 2018 2 Klinik für Innere Medizin-Pneumologie und Intensivmedizin, UKGM und Philipps-Universität Marburg, Marburg, Germany Treatment options in myocarditis and inflammatory cardiomyopathy Focus on i. v. immunoglobulins In 2012 we reviewed the treatment op- proBNP) and high-sensitivity (hs) tro- curtain of diabetic cardiomyopathy, viral tions in (peri)myocarditis and inflamma- ponin T or I as cardiac biomarkers of heart disease with or without inflamma- tory cardiomyopathy in a special issue of heart failure and necrosis, respectively. tion can be hidden. But which of the this journal devoted to heart failure and Of note, cardiac MRI is an important factors is then the major etiological de- cardiomyopathies [1]. Now, 5 years later, method for clarifying the presence of terminant? itistimelyandappropriatetotakestock inflammation or fibrosis in addition to This issue also holds true for alcoholic of old and new data on this topic. function and pericardial effusion, but it cardiomyopathy [8]. In these patients, al- cannot substitute endomyocardial biopsy cohol consumption of more than 40 g/day Evolution of diagnoses for establishing an etiologically based di- in men and more than 20g/day in women agnosis [1–5]. For the diagnosis of viral formorethan5yearsisthesomewhat In 2013, experts of the European Soci- vs. autoreactive (nonviral) myocarditis arbitrary diagnostic determinant for the ety of Cardiology (ESC) working group and for the diagnosis of eosinophilic or label of alcoholic cardiomyopathy.
    [Show full text]
  • View Pdf Copy of Original Document
    Phenotype definition for the Vanderbilt Genome-Electronic Records project Identifying genetics determinants of normal QRS duration (QRSd) Patient population: • Patients with DNA whose first electrocardiogram (ECG) is designated as “normal” and lacking an exclusion criteria. • For this study, case and control are drawn from the same population and analyzed via continuous trait analysis. The only difference will be the QRSd. Hypothetical timeline for a single patient: Notes: • The study ECG is the first normal ECG. • The “Mildly abnormal” ECG cannot be abnormal by presence of heart disease. It can have abnormal rate, be recorded in the presence of Na-channel blocking meds, etc. For instance, a HR >100 is OK but not a bundle branch block. • Y duration = from first entry in the electronic medical record (EMR) until one month following normal ECG • Z duration = most recent clinic visit or problem list (if present) to one week following the normal ECG. Labs values, though, must be +/- 48h from the ECG time Criteria to be included in the analysis: Criteria Source/Method “Normal” ECG must be: • QRSd between 65-120ms ECG calculations • ECG designed as “NORMAL” ECG classification • Heart Rate between 50-100 ECG calculations • ECG Impression must not contain Natural Language Processing (NLP) on evidence of heart disease concepts (see ECG impression. Will exclude all but list below) negated terms (e.g., exclude those with possible, probable, or asserted bundle branch blocks). Should also exclude normalization negations like “LBBB no longer present.”
    [Show full text]
  • Diabetic Cardiomyopathy
    4 178 E Levelt and others Diabetic heart disease 178:4 R127–R139 Review MECHANISMS IN ENDOCRINOLOGY Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review Eylem Levelt1,†, Gaurav Gulsin1 , Stefan Neubauer2 and Gerry P McCann1 1British Heart Foundation Cardiovascular Research Centre, University of Leicester, Glenfield Hospital, Leicester, UK, 2University of Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, Division of † Cardiovascular Medicine, Radcliffe Department of Medicine, Oxford, UK, (E Levelt is now at Multidisciplinary Correspondence Cardiovascular Research Centre and Biomedical Imaging Science Department, Leeds Institute of Cardiovascular and should be addressed Metabolic Medicine, University of Leeds, Leeds, UK) to E Levelt Email [email protected] Abstract Heart failure is a major cause of morbidity and mortality in type 2 diabetes. Type 2 diabetes contributes to the development of heart failure through a variety of mechanisms, including disease-specific myocardial structural, functional and metabolic changes. This review will focus on the contemporary contributions of state of the art non- invasive technologies to our understanding of diabetic cardiomyopathy, including data on cardiac disease phenotype, cardiac energy metabolism and energetic deficiency, ectopic and visceral adiposity, diabetic liver disease, metabolic modulation strategies and cardiovascular outcomes with new classes of glucose-lowering therapies. European Journal of Endocrinology European Journal European of Endocrinology (2018) 178, R127–R139 Introduction Diabetes has reached epidemic proportions and is now structural and haemodynamic changes are not directly among the top 10 causes of death worldwide (1). Type 2 attributable to other confounding factors such as coronary diabetes (T2D) is associated with an increased risk of both artery disease and hypertension, in patients with diabetes heart failure (HF) and cardiovascular mortality even in the (9).
    [Show full text]
  • Vascular Endothelial Dysfunction, a Major Mediator in Diabetic Cardiomyopathy
    www.nature.com/aps REVIEW ARTICLE Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy Maura Knapp1, Xin Tu1 and Rongxue Wu1 Diabetes mellitus is currently a major public health problem. A common complication of diabetes is cardiac dysfunction, which is recognized as a microvascular disease that leads to morbidity and mortality in diabetic patients. While ischemic events are commonly observed in diabetic patients, the risk for developing heart failure is also increased, independent of the severity of coronary artery disease and hypertension. This diabetes-associated clinical entity is considered a distinct disease process referred to as “diabetic cardiomyopathy”. However, it is not clear how diabetes promotes cardiac dysfunction. Vascular endothelial dysfunction is thought to be one of the key risk factors. The impact of diabetes on the endothelium involves several alterations, including hyperglycemia, fatty acid oxidation, reduced nitric oxide (NO), oxidative stress, inflammatory activation, and altered barrier function. The current review provides an update on mechanisms that specifically target endothelial dysfunction, which may lead to diabetic cardiomyopathy. Keywords: cardiomyopathy; diabetes; diabetic cardiovascular complications; endothelium; vascular; heart failure; metabolism Acta Pharmacologica Sinica (2019) 40:1–8; https://doi.org/10.1038/s41401-018-0042-6 INTRODUCTION Clinical manifestations of diabetic cardiomyopathy Cardiovascular disease is a major cause of morbidity and mortality Diabetic cardiomyopathy affects both type 1 and type 2 diabetic in diabetic patients. It has long been established that diabetes patients and is characterized by a variety of functional and significantly increases the risk of cardiovascular disease, with structural changes in the heart. In early stages of the disease, left diabetic men being two times more likely to suffer from ventricular diastolic dysfunction (LVDD) is the most prevalent congestive heart failure (CHF) than non-diabetic individuals and cardiac complication [8, 9].
    [Show full text]
  • Diabetic Cardiomyopathy and Subclinical Cardiovascular Disease the Multi-Ethnic Study of Atherosclerosis (MESA)
    Pathophysiology/Complications ORIGINAL ARTICLE Diabetic Cardiomyopathy and Subclinical Cardiovascular Disease The Multi-Ethnic Study of Atherosclerosis (MESA) 1 4 ALAIN G. BERTONI, MD, MPH JOSEPH F. POLAK, MD, MPH eart failure has become a frequent 1 5 DAVID C. GOFF,JR., MD, PHD MOHAMMED F. SAAD, MD, MRCP manifestation of cardiovascular dis- 1 6 RALPH B. D’AGOSTINO,JR., PHD MOYSES SZKLO, MD, DRPH 2 ease (CVD) among individuals with IANG IU PHD 7 H K L , RUSSELL P. TRACY, PHD diabetes (1). As the prevalence of diabetes 1 8 W. GREGORY HUNDLEY, MD AVID ISCOVICK MD, MPH 3 D S. S , increases, it will probably emerge as one JOAO A. LIMA, MD of the principal causes of heart failure in the U.S. (2–4). There is significant evi- dence of the existence of “diabetic cardio- OBJECTIVE — Studies have demonstrated increased left ventricular mass (LVM) and dia- myopathy,” described classically as heart stolic dysfunction among diabetic patients without clinical cardiovascular disease (CVD), but failure in the absence of obstructive coro- few have assessed the potential contribution of subclinical CVD to ventricular abnormalities in nary disease but now more often defining diabetes. We examined whether diabetic cardiomyopathy is associated with subclinical athero- sclerosis and if abnormalities are found with impaired fasting glucose (IFG). ventricular abnormalities seen in individ- uals without coronary disease including RESEARCH DESIGN AND METHODS — LVM, end-diastolic volume (EDV), and increased left ventricular mass (LVM) and stroke volume were measured by magnetic resonance imaging (MRI), and atherosclerosis was impaired diastolic function (3,5–8). Pro- assessed by coronary artery calcium and carotid intima-media wall thickness in 4,991 partici- posed mechanisms include deleterious ef- pants in the Multi-Ethnic Study of Atherosclerosis, a cohort study of adults aged 45–84 without fects of hyperglycemia, hypertension, and prior CVD.
    [Show full text]
  • Diabetic Cardiomyopathy: Understanding the Independent Relationship Between Diabetes and Heart Failure
    HCA Healthcare Scholarly Commons Internal Medicine Research & Publications 2-7-2020 Diabetic Cardiomyopathy: Understanding the Independent Relationship Between Diabetes and Heart Failure W. Tyler Crawley Rage Geringer MD HCA Healthcare, [email protected] Jason Snarr DO HCA Healthcare, [email protected] Elizabeth Hicks MD HCA Healthcare Oliwier Dziadkowiec HCA Healthcare, [email protected] Follow this and additional works at: https://scholarlycommons.hcahealthcare.com/internal-medicine Part of the Cardiology Commons, Cardiovascular Diseases Commons, Endocrine System Diseases Commons, Endocrinology, Diabetes, and Metabolism Commons, and the Nutritional and Metabolic Diseases Commons Recommended Citation Crawley WT, Geringer R, Snarr J, Hicks ME, Dziadkowiec O. Diabetic cardiomyopathy: understanding the independent relationship between diabetes and heart failure. Poster presented at: ACP Colorado Chapter Meeting; February 6-8, 2020; Colorado Springs, CO. This Poster is brought to you for free and open access by the Research & Publications at Scholarly Commons. It has been accepted for inclusion in Internal Medicine by an authorized administrator of Scholarly Commons. Diabetic Cardiomyopathy: Understanding the Independent Relationship Between Diabetes and Heart Failure. W. Tyler Crawley, OMS-III; Rage Geringer, MD; Jason Snarr, DO; M. Elizabeth Hicks, MD, Oliwier Dziadkowiec, MD HCA Sky Ridge Medical Center, Hospital Corporation of America Graduate Medical Education, Rocky Vista University College of Osteopathic Medicine Introduction Figures Discussion Type 2 diabetes mellitus (DM) and heart failure (HF) are common chronic disorders that The development of DCM is related to the effects of DM systemically, on the myocardium, 1 affect 29 million and 6.5 million Americans respectively . While both often occur individually, and directly on cardiomyocytes3.
    [Show full text]
  • Case Report on Dilated Cardiomyopathy in Type 2 Diabetes Mellitus Patient with Hypothyroidism
    Case report on dilated cardiomyopathy in type 2 diabetes mellitus patient with hypothyroidism A. Bharath Kumar, M. S. Umashankar*, A. Porselvi Department of Pharmaceutics, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, 603203, Kancheepuram district, Tamil nadu, India. Correspondence: M. S. Umashankar, Department of Pharmaceutics, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, 603203, Kancheepuram district, Tamil nadu, India. E_mail: [email protected] ABSTRACT Dilated cardiomyopathy (DCM) is an idiopathic condition manifesting decreased contractility of heart, which is irreversible and slowly progressive. DCM, thyroid disorder and diabetes mellitus are the most interlinked symptomatology. Thyroid disease is a common endocrine disorder associated with diabetic cardiomyopathy. The complications which have been exhibited are contractile dysfunction, systolic dysfunction, ventricular dysfunction and diastolic dysfunction, ventricular diastolic and systolic dysfunction. A case study of a 75-year-old female patient visited the general medicine OPD with chief complaints of shortness of the breath, swelling of legs, chest discomfort, severe constipation, fatigue and palpitation. The patient was advised to have electrocardiogram which showed atrial fibrillation with ventricular tachycardia, and the chest X-ray which revealed cardiomegaly. The patient was also undergone echocardiogram which showed dilated cardiomyopathy with severely decreased left ventricular systolic function and a reduced left ventricular ejection fraction of 39%. Thyroid function test revealed a low hormone level. A regular treatment and continued patient’s follow up care were suggested to the patient, and she manifested a progressive development of her condition. The patient was prescribed with discharge medications, and advised for a follow-up care. Keywords: Dilated cardiomyopathy, thyroid diseases, diabetes mellitus, diastolic and systolic dysfunction.
    [Show full text]
  • Diabetic Cardiomyopathy: from Pathophysiology to Treatment
    Hellenic J Cardiol 2014; 55: 411-421 Review Article Diabetic Cardiomyopathy: From Pathophysiology to Treatment 1 1 2 2 KONSTANTINOS TRACHANAS , SKEVOS SIDERIS , CONSTANTINA AGGELI , EMMANOUIL POULIDAKIS , 2 2 1 KONSTANTINOS GATZOULIS , DIMITRIOS TOUSOULIS , IOANNIS KALLIKAZAROS 1Department of Cardiology, Hippokration General Hospital, 2First Department of Cardiology, National University of Athens, Hippokration General Hospital, Athens, Greece Key words: Diabetic he close relationship between di- As was demonstrated in the Framingham cardiomyopathy, abetes mellitus and heart failure Heart Study, diabetes is a strong and in- diastolic dysfunction, has been known for many years dependent risk factor for developing heart myocardial fibrosis, Tand includes many mechanisms. In 1881, failure, leading this group of patients to systolic dysfunction. Leyden first claimed that diabetic cardio- a worse prognosis. The risk of heart fail- myopathy is a common complication of ure was 2.4-fold and 5-fold higher in dia- diabetes and one worthy of attention. In betic men and women, respectively, than 1888, Mayer reported that diabetes is a in non-diabetic subjects. The incidence of disorder of metabolism that can lead to heart failure in diabetic patients is still in- heart disease. Finally, the term “diabet- creased even after adjustment for age, hy- ic cardiomyopathy” was introduced by pertension, obesity, coronary artery dis- Rubler in 1972, after post mortem stud- ease or dyslipidemia.5 The close correla- ies in diabetic patients with heart failure tion between diabetes and heart failure Manuscript received: in whom alcohol, hypertension, coronary has been demonstrated in many studies. November 21, 2012; disease and other structural heart disease In the United Kingdom Prospective Dia- Accepted: had been ruled out as possible causes.1 betes Study (UKPDS) an increased preva- June 1, 2014.
    [Show full text]
  • The Heart of Creatures Is the Foundation of Life, the Prince of All, the Sun of Their Microcosm, from Where All Vigor and Strength Does Flow
    The heart of creatures is the foundation of life, the Prince of all, the sun of their microcosm, from where all vigor and strength does flow. -William Harvey, De Motu Cordis, 1628 University of Alberta The Role of TIMPs in Heart Disease by Vijay Saradhi Kandalam A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Physiology ©Vijay Saradhi Kandalam Fall 2012 Edmonton, Alberta Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of these terms. The author reserves all other publication and other rights in association with the copyright in the thesis and, except as herein before provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission. DEDICATION To family, friends, and colleagues who have supported my pursuit of realizing my potential. I would like to share this accomplishment with all of you, as without you I could not have achieved this. ABSTRACT Heart disease is a leading cause of morbidity and mortality in the world with a growing prevalence in a variety of manifestations. Many of the events that occur in the heart during the progression of disease have been explored to identify a causative mechanism to develop effective treatments and possibly a cure for heart disease.
    [Show full text]
  • The Mystery of Diabetic Cardiomyopathy: from Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities
    International Journal of Molecular Sciences Review The Mystery of Diabetic Cardiomyopathy: From Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities Petra Grubi´cRotkvi´c 1,* , Zrinka Planini´c 1 , Ana-Marija Liberati Pršo 1,2, Jozica Šiki´c 1,3, Edvard Gali´c 1,3 and Luka Rotkvi´c 4 1 Clinic of Internal Medicine, University Hospital “Sveti Duh”, Sveti Duh 64, 10000 Zagreb, Croatia; [email protected] (Z.P.); [email protected] (A.-M.L.P.); [email protected] (J.Š.); [email protected] (E.G.) 2 Faculty of Food Technology and Biotechnology, University of Zagreb, Pierottijeva 6, 10000 Zagreb, Croatia 3 School of Medicine, University of Zagreb, Salata 2, 10000 Zagreb, Croatia 4 Magdalena Clinic for Cardiovascular Diseases, Ljudevita Gaja 2, 49217 Krapinske Toplice, Croatia; [email protected] * Correspondence: [email protected] Abstract: Diabetic patients are predisposed to diabetic cardiomyopathy, a specific form of cardiomy- opathy which is characterized by the development of myocardial fibrosis, cardiomyocyte hypertrophy, and apoptosis that develops independently of concomitant macrovascular and microvascular dia- betic complications. Its pathophysiology is multifactorial and poorly understood and no specific Citation: Grubi´cRotkvi´c,P.; therapeutic guideline has yet been established. Diabetic cardiomyopathy is a challenging diagnosis, Planini´c,Z.; Liberati Pršo, A.-M.; made after excluding other potential entities, treated with different pharmacotherapeutic agents Šiki´c,J.; Gali´c,E.; Rotkvi´c,L. targeting various pathophysiological pathways that need yet to be unraveled. It has great clinical The Mystery of Diabetic importance as diabetes is a disease with pandemic proportions. This review focuses on the potential Cardiomyopathy: From Early mechanisms contributing to this entity, diagnostic options, as well as on potential therapeutic inter- Concepts and Underlying ventions taking in consideration their clinical feasibility and limitations in everyday practice.
    [Show full text]
  • Contemporary Echocardiographic Techniques in Early Detection of Diabetic Cardiomyopathy
    Journal of Cardiology & Current Research Review article Open Access Contemporary echocardiographic techniques in early detection of diabetic cardiomyopathy Abstract Volume 1 Issue 5 - 2014 Diabetic cardiomyopathy is defined as heart failure independent of hypertension, Slavica Mitrovska, Biljana Lazeska coronary artery and valve disease. It has multifactorial etiology and the pathogenesis is Department of Internal Medicine, Military Hospital, Macedonia still incompletely understood. Structural changes lead to functional alterations of the left ventricle (LV) and diastolic dysfunction is the earliest sign. It has long asymptomatic Correspondence: Slavica Mitrovska, Department of Internal period, but with the time leads to reduced contractile function. Diagnosis of diabetic Medicine, Military Hospital, Macedonia ul. Sole Stojcev br. 1-2/8, cardiomyopathy is a challenge for cardiologists. As an entity, it exists for more than 4 1000 Skopje, Macedonia, Tel 38971385267, decades, but no single diagnostic method yet and no established standard diagnostic criteria. Email Current technology and methods are still subjects of modification and they are not routinely used in daily practice. Therefore, late diagnosis of cardiovascular complications of diabetes Received: September 08, 2014 | Published: October 13, 2014 is very often, even at the stage of overt heart failure. Echocardiography is a diagnostic method of choice, from practical and economic point of view, but conventional techniques-two-dimensional (2D), M-mode echocardiography and Pulsed-waved (PW) Doppler analysis have limitations and provide inconclusive results. Contemporary techniques-Tissue Doppler Imagine, Color M-mode, 2D Speckle Tracking, strain and strain-rate are more sensitive and relatively independent to the loading conditions methods that provides comprehensive assessment of myocardial tissue velocities.
    [Show full text]